Lexaria Bioscience receives four patents for drug delivery technology

Lexaria Bioscience (NASDAQ: LEXX) completed enrollment for its Human Pilot Study #7, evaluating oral DehydraTECH-semaglutide against Novo's Wegovy. The study assesses safety, tolerability, and pharmacokinetic properties over five weeks, with dosing expected to complete in mid-November. This is the first multi-dose, multi-week study of SNAC-inclusive formulations.

Lexaria Bioscience (LEXX) signed a Material Transfer Agreement with PegBio to test Lexaria’s DehydraTECH drug delivery platform using PegBio’s proprietary GLP-1 molecule for animal studies. The goal is to assess pharmacokinetics and explore oral delivery for diabetes, obesity, and metabolic diseases. LEXX trades at $7.68, up 25.54%, after a 1-for-15 reverse split on Aug 3, 2026.

{"summary": "Samsung and Google opened preorders for their AI glasses, sparking a surge in Chinese AI glasses concept stocks. Siya Technology's P/E soared to 1,355x. Meta dominates the AI glasses market, but Samsung-Google's entry could shift competition. Global smart glasses shipments grew 127% year-on-year in the first half of 2026, with Meta holding 81.3% market share.

Rakuten Group and AST SpaceMobile formed a joint venture, Rakuten AST, to build a satellite communications network in Japan. The project, supported by up to 148 billion yen in funding, aims to provide direct-to-device connectivity for smartphones, enhancing disaster resilience. Rakuten AST plans to commence operations by March 2029, leveraging AST SpaceMobile's satellites for high-speed internet access.

Editas Medicine (NASDAQ:EDIT) plans human trials after its gene therapy reduced LDL cholesterol by 90% in primates. The company raised $125M, extending its cash runway to 2028. CFO Amy Parison said funds will support trial completion. CEO O'Neill noted potential approval path for LDL reduction, pending regulatory agreement.

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.